Advertisement

Molecular Medicine

, Volume 18, Issue 6, pp 930–937 | Cite as

HMGB1 Mediates Cognitive Impairment in Sepsis Survivors

  • Sangeeta S Chavan
  • Patricio T Huerta
  • Sergio Robbiati
  • S I Valdes-Ferrer
  • Mahendar Ochani
  • Meghan Dancho
  • Maya Frankfurt
  • Bruce T Volpe
  • Kevin J Tracey
  • Betty Diamond
Open Access
Research Article

Abstract

Severe sepsis, a syndrome that complicates infection and injury, affects 750,000 annually in the United States. The acute mortality rate is approximately 30%, but, strikingly, sepsis survivors have a significant disability burden: up to 25% of survivors are cognitively and physically impaired. To investigate the mechanisms underlying persistent cognitive impairment in sepsis survivors, here we developed a murine model of severe sepsis survivors following cecal ligation and puncture (CLP) to study cognitive impairments. We observed that serum levels of high mobility group box 1 (HMGB1), a critical mediator of acute sepsis pathophysiology, are increased in sepsis survivors. Significantly, these levels remain elevated for at least 4 wks after CLP? Sepsis survivors develop significant, persistent impairments in learning and memory, and anatomic changes in the hippocampus associated with a loss of synaptic plasticity. Administration of neutralizing anti-HMGBl antibody to survivors, beginning 1 wk after onset of peritonitis, significantly improved memory impairments and brain pathology. Administration of recombinant HMGB1 to naíve mice recapitulated the memory impairments. Together, these findings indicate that elevated HMGB1 levels mediate cognitive decline in sepsis survivors, and suggest that it may be possible to prevent or reverse cognitive impairments in sepsis survivors by administration of anti-HMGB1 antibodies.

Introduction

Severe sepsis, the clinical syndrome that complicates infection and injury, has an incidence of more than 750,000 cases per year, and kills more than 210,000 individuals in the United States annually (1, 2, 3). Although it is the leading cause of hospitalized death, the therapeutic choices are limited, and the only FDA-approved therapy, “activated protein C,” recently was pulled from the market. Moreover, the significance of this problem extends long after hospitalization, because survivors of severe sepsis develop complications of nonresolving inflammation that persist following discharge from the hospital (4). Survivors are frequently unable to return to work, and develop significant cognitive impairment, immunological dysfunction and poor quality of life indicators (1,5). More than half of the 540,000 severe sepsis survivors discharged annually from the hospital are dead within 5 years (3). There is clearly a significant need to understand mechanisms that can mediate cognitive impairment in severe sepsis survivors.

The pathogenesis of severe sepsis and associated organ damage is attributable to cytokines and other pathogenic mediators. Inflammation in tissues can persist long after the inciting trauma or infection (a phenomenon termed “nonresolving inflammation”) that significantly impairs organ function (6). There has been a long-standing interest in targeting specific molecular mechanisms for therapeutic benefit. Indeed, since the demonstration that monoclonal anti-tumor necrosis factor (anti-TNF) antibodies can prevent lethal septic shock in bacteremic baboons, there have been more than 11,500 publications addressing the role of cytokines in causing organ dysfunction during severe sepsis. A major limitation of this antibody approach in the clinic is that the excessive production of cytokines is established early after the onset of infection or injury (7). Indeed, by the time severe sepsis is recognized, the majority of patients do not have elevated TNF levels; rather, levels of HMGB1, and other late mediators of sepsis are elevated significantly. Importantly, serum HMGB1 levels remained elevated in sepsis survivors at the time of hospital discharge (8), and, until now, the importance of elevated HMGB1 levels in sepsis survivors has not been studied.

In considering the hypothesis that HMGB1 mediates cognitive decline in sepsis survivors, previous studies indicate that TNF, IL-1 and HMGB1 occupy critical roles in modulating neuronal activity underlying cognition and behavior. TNF modulates the expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and N-methyl-D-aspartate receptors (NMDARs) on neurons, which are critical in learning and memory (9). IL-1ß and HMGB1 also modulate NMDARs, with functional consequences that can contribute to altered memory (10,11). HMGB1 regulates neuronal and dendritic growth, and, as do TNF and IL-1, induces sickness behavior associated with fever, anorexia, withdrawal and impaired cognition. Administration of anti-TNF antibody and anti-IL-1 antibody in acute murine injury and infection models significantly improves cognitive abnormalities (12,13). Clinical studies of serum cytokine levels in severe sepsis survivors indicate that HMGB1 levels are increased significantly at the time of hospital discharge, whereas TNF and IL-1 levels are not (8,14).

Accordingly, here we established severe sepsis in mice to study the role of HMGB1 in mediating cognitive dysfunction in the survivors. The results show that serum HMGB1 levels are elevated significantly for weeks after sepsis. Whereas animals exhibit outwardly normal behavior, cognitive testing reveals significant impairments in learning and memory. As administration of neutralizing anti-HMGB1 monoclonal antibody to sepsis survivors confers significant protection against memory impairment, and administration of rHMGB1 to naíve mice induces cognitive impairment, these results implicate a pathogenic role of HMGB1 in sepsis survivors.

Materials and Methods

Animals

Experiments with male BALB/c mice (6–8 wks old, Charles River Laboratories, Wilmington, MA, USA) were performed in accordance with the National Institutes of Health (NIH) Guidelines under protocols approved by the Institutional Animal Care and Use Committee (IACUC) Committee of the Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, New York, USA.

Surgery for Cecal Ligation and Puncture (CLP)

Severe polymicrobial sepsis was induced by CLP (15). Mice were anesthetized using ketamine (100 mg/kg) and xylazine (8 mg/kg) administered intramuscularly (i.m.). A midline incision was made to expose the cecum. After ligation with a 4-0 silk ligature below the ileocecal valve, the cecum was punctured once with a 22-gauge needle and stool (approximately 1 mm) was extruded from the hole. The perforated cecum was placed back into the abdominal cavity, and the incision was closed with two layers of 6-0 Ethilon running sutures. All animals received normal saline resuscitation (20 mL/kg of body weight, injected subcutaneously [s.c.]), and a single dose of antibiotics (Primaxin, 0.5 mg/mouse in 200 µL sterile saline, injected s.c.) (Merck & Co. Inc., Whitehouse Station, NJ, USA) immediately after CLP. Sham-operated animals had the cecum isolated and then returned to the peritoneal cavity, without being ligated or punctured. These animals also received an antibiotic treatment and resuscitative fluid as described above.

Serum HMGB1 Determination

Mice were subjected to CLP surgery or sham surgery as described above, and the survivors were monitored for 12 wks. To determine levels of HMGB1 in the serum, mice were euthanized at indicated time points, and blood was collected by cardiac puncture. Serum HMGB1 concentrations were determined by Western immunoblotting analysis as described previously (16). In brief, serum samples (100–200 µL) were ultrafiltered with Centricon 100 (EMD Millipore Corporation, Billerica, MA, USA). The eluate was fractionated by SDS-PAGE, transferred to a poly(vinylidene difluoride) immunoblot membrane (Bio-Rad Laboratories, Hercules, CA, USA), and probed with either specific anti-HMGB1 antiserum (1:250 dilution) or purified IgG from anti-HMGB1 antiserum (5 μg/mL) for Western blot analysis. Polyclonal anti-HMGB1 IgG was purified by using protein-A agarose, according to the manufacturer’s instructions (Pierce Biotechnology Inc., Rockford, IL, USA). Western blots were scanned with a Bio-Rad image analyzer (Bio-Rad), and the levels of HMGB1 were determined by reference to standard curves generated with purified HMGB1.

Administration of Anti-HMGB1 Monoclonal Antibody

For antibody administration, animals subjected to CLP surgery were randomized into two groups after 7 d. Anti-HMGB1 monoclonal antibody (IgG2b) or isotype control antibody (50 µg/mouse, intraperitoneally [i.p.]) was administered once a day on 3-d intervals (d 7, 9 and 11 after CLP). Animals were followed for 4 wks, and subjected to behavioral assessment.

HMGB1 Administration to Naíve Mice

Recombinant HMGB1 was prepared as described previously (15). Contaminating lipopolysaccharide (LPS) from protein preparations was removed by Triton X-114 extraction as described previously (16). Residual LPS is less than 1 pg/ µg protein. Purified recombinant HMGB1 or vehicle was administered to 6–8 wk-old healthy BALB/c mice (500 µg diluted in 350 µL of PBS 1 × every day, i.p.) for 3 wks. Animals were subjected to behavioral assessment 1 wk later.

Behavioral Assessment

The behavioral procedures have been described previously (17). All testing occurred between 10:00 and 18:00 h and the mice were between 10 wks and 6 months old. Each mouse was subjected to a multistage assessment consisting of a primary screen, adapted from Irwin (1968) (18) and the first stage of the SHIRPA procedure (18,19), an open-field test that measured spontaneous locomotion, a rotarod test that measured motor coordination, a black-and-white alley test that measured anxiety (20) and a navigational test that measured spatial working memory, modified from Deacon and Rawlins (21). Each of these tests was separated by at least 1 d.

The primary screen (Table 1) started with anatomical parameters (coat length, hair length and hair morphology), followed by observation in a cylindrical glass flask (height 15 cm, diameter 11 cm), which measured body position, spontaneous activity, respiratory rate, tremor occurrence, defecation and urination. Transfer to an arena (55 cm × 33 cm) allowed for measuring of transfer arousal, latency to move in the arena and locomotion in the arena. This was continued with manipulations for measuring piloerection, palpebral closure, startle response, gait, pelvic elevation, tail elevation, touch escape, positional passivity, trunk curl, limb grasping, visual placing, grip strength, body tone, pinna reflex, corneal reflex, toe pinch, body length, tail length, lacrimation, whisker morphology, provoked biting, salivation, heart rate, abdominal tone, skin color and limb tone. Measuring several reflexes (wire maneuver, righting reflex, contact righting, negative geotaxis) completed the screen. Throughout the screen, incidences of fear to the experimenter, irritability, aggressivity to the experimenter, vocalizations and abnormal behavior were recorded. Finally, body weight was measured. The observed parameters were grouped according to five functional categories, which were: muscle and spinal function; spinocerebellar function; sensory function; neuropsychiatric function; and autonomic function (19). The summed scores for each function were averaged across mice with similar treatment (CLP or sham surgery) and these were then subjected to statistical analysis.
Table 1

Primary screen variables contributing to the evaluation of specific functions.

Function

 

Variables

 

1. Muscle and spinal function

Abdominal tone

Grip strength

Spontaneous activity

 

Body position

Limb grasping

Tail elevation

 

Body tone

Limb tone

Trunk curl

 

Contact righting

Pelvic elevation

Urination

 

Defecation

Positional passivity

Visual placing

 

Gait

Righting reflex

Wire maneuver

2. Spinocerebellar function

Abdominal tone

Grip strength

Righting reflex

 

Body position

Limb grasping

Tail elevation

 

Body tone

Limb tone

Trunk curl

 

Contact righting

Pelvic elevation

Visual placing

 

Gait

  

3. Sensory function

Corneal reflex

Provoked biting

Touch escape

 

Gait

Righting reflex

Transfer arousal

 

Negative geotaxis

Toe pinch

Visual placing

 

Pinna reflex

  

4. Neuropsychiatric function

Abnormal behavior

Latency to move

Startle response

 

Aggressivity

Locomotion

Touch escape

 

Body position

Negative geotaxis

Transfer arousal

 

Body tone

Positional passivity

Tremor

 

Contact righting

Provoked biting

Vocalizations

 

Fear

Righting reflex

Wire maneuver

 

Irritability

Spontaneous activity

 

5. Autonomic function

Defecation

Piloerection

Startle response

 

Heart rate

Respiratory rate

Tail elevation

 

Lacrimation

Salivation

Urination

 

Palpebral closure

Skin color

 

For the open-field test, each mouse was placed in an empty chamber (30 cm × 50 cm) with 15-cm high walls made of opaque white acrylic for 1 min under dim red light. Movement was recorded from a centrally placed video camera using automated video tracking software to record the distance traveled (EthoVision, Noldus, Attleboro, MA, USA). For the rotarod test, mice were placed individually on a rotating drum (ENV-576M, Med Associates Inc, St. George, VT, USA), which accelerated from 4 to 40 rpm over a course of 5 min. The time at which the mouse fell off the drum was recorded. The test was repeated 10 times for each mouse with an interval of at least 1 h between trials. The room was illuminated with low-level white lights. The black-and-white alley test occurred in two stages with a habituation alley (painted gray, 120 cm long, 9 cm wide, 30 cm high) and a testing alley (same dimensions, one half-painted black and the other white, with 1-cm high wire barrier separating the two halves). The purpose of the habituation alley was to familiarize the mouse, immediately before testing, to an environment structurally similar to the testing alley, potentially exacerbating the black-and-white contrast in the latter. Each mouse was put in the habituation alley for 30 s, then directly transferred into the test alley for a 5-min testing trial. The animal was placed near the closed end of the white half, facing the wall. The initial latency to enter (all four paws) into the dark half, and the total time spent in each half were recorded by software (Ethovision, Noldus). Between each mouse, feces and urine were carefully removed and the test alley thoroughly wiped with a damp tissue.

The navigational test that measured spatial working memory was modified from Deacon and Rawlins (21). The apparatus (termed “clock maze”) was a circular base platform (diameter, 85 cm) surrounded by a clear wall (30 cm high), sealed to the base by aquarium sealant to make it waterproof. Cold water (20° C ± 1° C) was added to a depth of 2 cm, sufficient to wet the underside of the belly of mice. The perimeter wall was pierced by 12 holes, 4 cm in diameter, arranged equidistantly around the circumference so that they were 23 cm apart, like the 12 h on a clock face. The lower edge of each hole was 3 cm above the maze floor, that is, at mouse head level. Eleven of these tubes were sealed with black plugs, flush with the internal pool wall surface; one was open and led to an escape pipe, which was 4 cm in diameter, made of black flexible plastic. Thus, from within the clock maze, the true exit looked similar to the decoys, even to the human eye. The pool was surrounded by distal unmoving cues (face masks, large curtain, a bench), which were illuminated by focal white lights within a darkened testing room. Besides the clock maze, there was a pretraining box (28 cm long × 8 cm wide × 30 cm high), which was made of black wood, open on the top and with one short side (made of an acrylic sheet) containing an escape tube of black plastic (diameter, 4 cm, length, 4 cm), with its lower edge at 3 cm above the base, at mouse head height. The escape pipe, as used on the clock maze, was fitted onto the tube. There was also a pretraining tunnel (rectangle, 39 cm long × 24 cm wide × 30 cm high), made of clear plastic, and was filled with water to 2.5 cm. It had two black plastic escape tubes set in diagonally opposite corners of the short sides, centered 5 cm above the base and 5 cm from the adjacent longer wall. One tube was open and leads to the escape pipe, while the other was sealed with a black plug. For each apparatus, the task was to escape into the open tube and connected pipe; the pipe was then removed and the mouse was transported to the nearby home cage. For pretraining, each mouse was first placed in the far end of the pretraining box to learn the principle of escaping into the tube. The mice received four trials in 1 d with each trial lasting a maximum of 60 s. The next day, mice received four trials in the pretraining tunnel. The animal was placed facing one of the long sides in a semi-random fashion (not more than three consecutive times the same way) and the time taken to enter the open tube was recorded by software (Ethovision, Noldus). Errors were defined as approaching the closed tube (within a head’s length). Maximum trial length was 60 s. For the working memory task, a mouse underwent four trials per day in the clock maze for 3 consecutive days. The target remained in a fixed location during the initial four trials, but it was switched to a different location during the next four trials, and yet another location for the final four trials. Therefore, each mouse was required to learn three different targets during the test. The latency to reach the target was recorded by software (Ethovision, Novus) with a maximum of 60 s for each trial. A learning score (LS) for each animal was obtained from the latencies (“Lat”) for each trial (Lat2 to Lat12), using the following equation; LS = ([(1/Lat2) + (1/Lat3) + (1/Lat4) + (1/Lat6) + (1/Lat7) + (1/Lat8) + (1/Lat10) + (1/Lat11) + (1/Lat12)]/9), which averaged the inverses of the latencies in nonnovel trials.

Histology

Brain circulation was replaced with heparinized normal saline, followed by 4% paraformaldehyde. Brains were removed, postfixed for 1 h, and infiltrated with 30% sucrose overnight at 4°C. A 5-mm coronal brain slab was isolated in a brain mold, mounted on a freezing stage, and sectioned by microtome at 40 µm. Sections were collected in 0.1 mol/L PB (pH7.4). Every fourth section was mounted in 0.05 mol/L PB on gelatin-coated slides, air-dried and stained with cresyl violet (22).

Golgi staining was performed with the FD Rapid Golgi Stain kit (FD Neuro Technologies, Ellicott, City, MD, USA). Mice were saline perfused and brains were immersed for 2 wks in an impregnation solution, and then cryoprotected for 48 h to 1 wk and cut on a cryostat; 100 µm sections were transferred to gelatin-coated slides. After drying, slides were stained and cover slipped. Quantitation of apical dendritic spines in neurons in which the cell body was in the CA1 region and which were whole and unbroken into the projection field was performed as described (23), except that the images of the neurons were acquired at 100 × oil with a Zeiss Axio imager. A Z-stack of the neuron cell body in the CA1 region and distal dendritic field was captured in 0.5µm steps. The images were transferred to an automated program for counting and analysis (Neurolucida, MBF Bioscience, Williston, VT, USA.)

Statistical Analysis

Data are presented as mean ± SEM, mean ± SD or median (25% quartile/75% quartile) as indicated. We used factorial analysis of variance (ANOVA), repeated measures ANOVA, Student t test, MannWhitney test and Mood’s median test to examine statistical significance, which was defined as P < 0.05.

Results

Serum HMGB1 Levels are Increased Significantly in Sepsis Survivors

As compared with prototypical early cytokine mediators of sepsis, for example, TNF and IL1, which increase early during the syndrome but then return to normal levels, HMGB1 levels increase later (24). To investigate whether HMGB1 levels remained elevated in sepsis survivors, BALB/c mice were subjected to cecal ligation and puncture, a clinically relevant animal model of severe sepsis characterized by polymicrobial infection or to sham surgery (15). Animals were monitored for 12 wks, and serum samples collected for determination of HMGB1 levels by quantitative Western blot analysis. Serum HMGB1 levels were elevated significantly for weeks in sepsis-surviving mice, only returning to baseline after 12 wks (Figure 1).
Figure 1

Serum HMGB1: Serum samples were harvested from murine sepsis survivors or sham surgery survivors at each indicated time point (n = 4 to 6 mice per time point), and assayed for HMGB1 by Western blot. Densitometry and a standard curve were used for quantitation. Data: mean ± SE. *p < 0.05.

Sepsis Survivors Exhibit Persistent Learning and Memory Impairment

There is an improved understanding that interactions between innate immune mediators and brain underlie normal cognitive function, as well as the cognitive impairment that develops after injury or infection. Accordingly, we reasoned that sustained elevation of HMGB1 levels following sepsis might contribute to cognitive or behavioral impairment. We subjected mice to CLP or sham surgery (n = 20 in each group), and assessed behavior and cognitive function. Both groups behaved comparably across the measurement parameters (Table 1). Memory function assessed in a clock maze task, in which mice use visual cues placed around the maze to navigate to an exit, differed between the groups. Proper performance of this task depends on a functional hippocampus. As shown in Figure 2A, sepsis survivors exhibited significant impairment in this task as compared with sham surgery mice at 4 wks following CLP or the sham procedure. This impairment persisted for at least 4 months following the onset of severe sepsis (Figure 2B).
Figure 2

Cognitive and behavioral assessments of sepsis surviving mice. (A) Mice (CLP, n = 20, sham surgery, n = 20) were assessed for their ability to find the exit (indicated by a white box in the top view of the clock maze) in the spatial task. (B) CLP-surviving mice needed significantly more time to exit the maze at 1 month and 4 months following insult (**P < 0.01). (C) Sham surgery and CLP mice behaved equivalently in the primary screen as shown by their scores in muscle and spinal function, spinocerebellar function, sensory function, neuropsychiatric function and autonomic function at 1 month following CLP or sham surgery (see Methods for details). Sham surgery and CLP mice behaved (D) equivalently on the rotarod task, (E) exhibited equivalent locomotion and (F) displayed a similar level of anxiety in the black-white alley.

To test whether this was an isolated neurological defect or whether there were additional cognitive or behavioral impairments, CLP and sham-operated mice were subjected to further behavioral assessment. We found that the two groups had comparable performance on all the tasks (Table 2 and Figures 2CF), indicating that the memory impairment in the clock maze task was selective.
Table 2

Primary screen reveals unaltered behavioral variables in sepsis-surviving mice.a

No

Variable

Scale range

Sham (n = 20)

CLP (n = 20)

Chi-square

d.f.

P

1

Coat length

0–4

0 (0/0)

0 (0/0)

0

1

1

2

Hair length

0–3

0 (0/0)

0 (0/0)

0

1

1

3

Hair morphology

0–2

0 (0/0)

0 (0/0)

1.03

1

0.3112

4

Body position

0–8

5 (3/5)

5 (3/5)

3.24

1

0.0717

5

Spontaneous activity

0–8

3 (3/5)

5 (3/5)

2.56

1

0.1097

6

Respiratory rate

0–3

2 (2/2)

2 (2/2)

0

1

1

7

Tremor

0–2

0 (0/0)

0 (0/0)

0

1

1

8

Defecation

0–13

4 (2/7.5)

4(2/5.5)

0.42

1

0.5186

9

Urination

0–1

0 (0/0)

0(0/1)

0.53

1

0.4652

10

Transfer arousal

0–6

5 (4/5)

5 (4/5)

0

1

1

11

Latency to move

0–10

2 (1/2.5)

2 (1/3)

0.13

1

0.7233

12

Locomotion in arena

0–26

11 (7/14.5)

10.5 (9/12.75)

0.42

1

0.5186

13

Piloerection

0–1

0 (0/0)

0 (0/0)

0

1

1

14

Palpebral closure

0–2

0 (0/0)

0 (0/0)

0

1

1

15

Startle response

0–3

1 (1/1)

1 (1/1)

0

1

1

16

Gait

0–3

0 (0/0)

0 (0/0)

0

1

1

17

Pelvic elevation

0–3

2 (2/2)

2(2/2)

0

1

1

18

Tail elevation

0–2

1 (1/1)

1 (1/1)

1.03

1

0.3112

19

Touch escape

0–3

1 (0/2)

1 (0/2)

0.11

1

0.7357

20

Positional passivity

0–4

1.5 (0/4)

3 (0.5/4)

0.91

1

0.3422

21

Trunk curl

0–1

0 (0/0)

0 (0/0)

1.03

1

0.3112

22

Limb grasping

0–1

1 (0/1)

1 (0/1)

0

1

1

23

Visual placing

0–4

2 (1.25/2)

2(2/2)

0

1

1

24

Grip strength

0–4

2 (2/2.75)

2 (1.25/2.75)

0

1

1

25

Body tone

0–2

0 (0/1)

0 (0/1)

0.44

1

0.5073

26

Pinna reflex

0–2

1 (0/1)

1 (1/1)

0

1

1

27

Corneal reflex

0–3

1 (1/1)

1 (1/1)

0.36

1

0.5483

28

Toe pinch

0–4

1.5 (1/2.25)

1 (0/2)

0.4

1

0.525

29

Body length

0–100

90 (90/95)

90 (85.5/95)

0

1

1

30

Tail length

0–100

90 (90/90)

90 (85/90)

0

1

1

31

Lacrimation

0–1

0 (0/0)

0 (0/0)

0

1

1

32

Whisker morphology

0–1

0 (0/0)

0 (0/0)

1.03

1

0.3112

33

Provoked biting

0–1

0 (0/0)

0 (0/0.5)

1.56

1

0.2119

34

Salivation

0–2

0 (0/0)

0 (0/0)

2.11

1

0.1468

35

Heart rate

0–2

1 (1/1)

1 (1/1.5)

0.63

1

0.4292

36

Abdominal tone

0–2

1 (0/1)

0 (0/1)

1.62

1

0.2036

37

Skin color

0–2

1 (1/1)

1 (1/1)

0

1

1

38

Limb tone

0–4

1.5 (0.75/2)

1 (0/1.75)

2.56

1

0.1098

39

Wire maneuver

0–4

0 (0/1)

0 (0/0.5)

0.48

1

0.4902

40

Righting reflex

0–3

0 (0/0)

0 (0/0)

2.11

1

0.1468

41

Contact righting

0–1

1 (1/1)

1 (1/1)

0

1

1

42

Negative geotaxis

0–4

0 (0/0)

0 (0/0)

0.17

1

0.6773

43

Fear to experimenter

0–1

0 (0/0)

0 (0/0)

0.78

1

0.3758

44

Irritability

0–1

0 (0/0)

0 (0/0)

0

1

1

45

Aggressivity

0–1

0 (0/0)

0 (0/0)

1.03

1

0.3112

46

Vocalizations

0–1

0 (0/1)

0 (0/0)

4.8

1

0.0285

47

Abnormal behavior

0–1

0 (0/0)

0 (0/0)

0

1

1

48

Body weight

grams

27.8 (26.725/ 31.975)

27.75 (26.45/ 30.025)

0

1

1

aThe table lists the medians (25%/75% interquartile) for the 48 variables in the order they were measured. The nonparametric Mood’s median test was used to examine statistical significance. Chi-square, degrees of freedom (d.f.) and probability (P) values are shown. We found that only the vocalizations variable was different at the P < 0.05 level.

Administration of Anti-HMGB1 Antibodies Improves Cognitive Impairment in Sepsis Survivors

We next explored whether neutralization of circulating HMGB1 improved cognitive impairment. The rationale to target HMGB1 with a neutralizing monoclonal antibody was based on the following considerations. First, we wished to avoid the possibility that antibodies to TNF or IL-1 might delay the clearance of microorganisms and potentially increase the risk of infection. Second, TNF and IL-1 levels return to baseline by 24 to 72 h after the acute insult, a very limited therapeutic window, and we did not wish to inhibit cytokine levels in the normal range. In contrast, HMGB1 levels remain significantly elevated for weeks, a therapeutic window that can be exploited readily. Neutralizing anti-HMGB1 antibody or isotype control antibody was administered to sepsis survivors on d 7, 9 and 11 after sepsis. The antibodies were unmodified IgG2b which has a half-life of 21 d. Spatial memory was assessed in these animals at 4 wks after sepsis. As shown in Figure 3, mice receiving anti-HMGB1 antibody exhibited significantly reduced serum HMGB1 levels, and significant improvement in spatial memory function as compared with mice that received isotype control antibody. This indicates that high levels of circulating HMGB1 in sepsis survivors either directly or indirectly mediate the after sepsis cognitive impairment.
Figure 3

Preservation of memory function by neutralizing HMGB1 (A) Neutralizing anti-HMGB1 antibody was administered to CLP mice at 1 wk after sepsis. Serum levels of HMGB1 were analyzed at 4 wks after CLP (*P < 0.05). (B) CLP mice were given anti-HMGB1 monoclonal antibody or isotype control antibody and subjected to the clock maze task. (C) Mice receiving anti-HMGB1 antibody performed significantly better than those receiving control antibody (**P < 0.01).

Systemic Administration of HMGB1 Causes Memory Impairment

To explore the critical role of HMGB1 in memory impairment in sepsis-surviving mice, we administered rHMGB1 or vehicle daily for a period of 3 wks to naíve mice and assessed memory function 1 wk later. Mice receiving HMGB1 developed significantly impaired memory function in the clock maze task (Figure 4). Thus, exposure to systemically elevated levels of HMGB1 for a period of 3 wks is sufficient to mediate cognitive impairment by 1 month after the initial inflammatory insult.
Figure 4

Memory impairment in mice receiving HMGB1. (A) Mice were given daily injections of HMGB1 or saline and subjected to training on the clock maze task. (B) HMGB1 caused a significant decline in memory function (*P < 0.05).

Altered Hippocampal Structure is Present in Sepsis-Surviving Mice

To assess whether HMGB1 mediated structural changes in the hippocampus, brains were sectioned and prepared for histopathological examination. Sections from sepsis survivors and sham surgery mice appeared grossly normal, with no obvious loss of hippocampal neurons at 4 wks after onset of sepsis, a time at which the mice exhibited memory impairment (Figure 5A). However, as demonstrated in Figures 5B and C, spine density on dendritic processes of CA1 neurons was reduced significantly in sepsis survivors as compared with controls. This abnormal pattern persisted for at least 4 months following the onset of sepsis. Importantly, it was not present at 2 wks following the onset of sepsis, indicating that dendritic degeneration develops progressively over time in sepsis survivors, and is not caused by the onset of acute sepsis. Administration of neutralizing HMGB1 conferred significant protection against the loss of dendritic spines (Figure 5D). Together with prior studies suggesting that a loss of dendritic processes is associated with synaptic plasticity and memory function, our results suggest that the mechanism of impaired cognition in sepsis survivors mediated by HMGB1 is, at least in part, a loss of hippocampal spine density.
Figure 5

Neuroanatomical assessments in the hippocampus. (A) Representative cresyl violet-stained sections showed no gross abnormalities in the hippocampus of CLP mice when compared with sham surgery mice. (B) Golgi staining of CA1 neurons in the hippocampus, 4 wks after CLP or sham surgery (bar, 500 µm). (C) Quantification of CA1 apical dendritic spine density (spines per μn, mean ± SD) at 2 wks, 4 wks and 4 months after CLP or sham surgery. The sham group had significantly more spines at the later time points (*P < 0.05, three to four mice in each group; three to six dendritic arbors from each animal). (D) Mice that were treated with anti-HMGB1 antibody (Ab) following CLP exhibited a density of dendritic spines comparable to sham animals, 4 wks after surgery (three animals, six dendritic arbors from each animal). At right, Golgi-stained section of CA1 neuron from a CLP animal that was treated with anti-HMGB1 Ab (bar, 50 µm).

Discussion

This study demonstrates that mice surviving severe sepsis following cecal ligation and puncture develop significant memory impairment similar to the clinical problem observed in patients that have survived severe sepsis. While there are other minor functional limitations in patients following sepsis, the major impairment is cognitive. Multiple cytokines are released into the circulation as a consequence of polymicrobial sepsis (25). The early cytokine response includes IL-1 and TNF, both of which have been implicated in acute memory impairment in models of sterile inflammation. Neutralizing these cytokines during infection is potentially hazardous, and indeed there are warnings against the use of these immunosuppressive agents in the context of infection. In sepsis survivors, IL-1 and TNF levels have returned to baseline levels, but HMGB1 levels are high. The role of HMGB1 in mediating memory deficits had not been previously been explored, and here we show that sustained elevations in HMGB1 mediate memory impairment.

Administration of neutralizing HMGB1 beginning 1 wk after CLP improved memory function, indicating that HMGB1 was necessary for pathogenesis, and administration of rHMGB1 induced memory impairment, indicating that HMGB1 is sufficient for pathogenesis. HMGB1 levels increase after the onset of infection or sterile injury, so it is plausible to study further the role of this cytokine in mediating cognitive impairment and memory dysfunction in other disease models.

How systemic elevations in HMGB1 cause loss of dendritic spines and associated memory dysfunction is unknown. Indeed, how systemic inflammation, in general, is communicated to the brain is not well understood. It is possible that HMGB1, acting on RAGE receptors or Toll-like receptors (TLR) 2, 4, 7 or 9, directly activates peripheral nerves and an inflammatory circuit is transduced into neural signaling. Alternatively, HMGB1 may act on brain microvasculature endothelial cells either to breach blood-brain barrier integrity and expose the brain to neurotoxic substances in the circulation or to activate brain endothelial cells to alter the abluminal milieu with release of cytokines and other inflammatory mediators such as prostaglandins into brain parenchyma. HMGB1 also may penetrate porous regions of brain microvasculature, binding directly to receptors on glial cells and neurons. It also is plausible that high systemic levels of HMGB1 lead to increased levels of another, as yet unidentified, inflammatory mediator that then leads to brain dysfunction through any of the mechanisms described above.

Conclusion

Our findings indicate that neutralizing HMGB1, beginning 1 wk after the onset of sepsis, confers significant protection against memory impairment. This impairment evolves over time in sepsis survivors, but additional work is needed to reveal the mechanism and kinetics that relate elevated HMGB1 levels to the development of functional hippocampal lesions. The loss of dendritic processes is associated with impaired synaptic plasticity, which is the functional substrate of memory. It is likely that loss of dendritic processes is mediated by macroautophagy. That this might be stimulated by HMGB1 is the focus of ongoing investigation. Indeed, studies are underway to determine which inflammatory cytokines, if any, are present in the brain of CLP-surviving mice and which are produced within the brain.

The data presented here indicate that elevated HMGB1 levels in serum impair the structure and function of hippocampal neurons that underlie normal cognition. Of potential clinical importance, this study demonstrates that there may be a window of opportunity following sepsis in which neural protection can be achieved by administration of anti-HMGB1 antibodies to prevent or reverse cognitive impairment.

Disclosure

The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.

Notes

Acknowledgments

This study was supported by a grant from the National Institute of Health (NIGMS GM62508 to KJ Tracey). The authors would like to thank Thomas W Faust and Tomas S Huerta for help in the behavioral assessments, and Roseann Berlin for technical assistance.

References

  1. 1.
    Iwashyna TJ, Ely EW, Smith DM and Langa KM. (2010) Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 304:1787–94.CrossRefGoogle Scholar
  2. 2.
    Perl TM, Dvorak L, Hwang T and Wenzel RP. (1995) Long-term survival and function after suspected gram-negative sepsis. JAMA. 274:338–45.CrossRefGoogle Scholar
  3. 3.
    Quartin AA, Schein RM, Kett DH and Peduzzi PN. (1997) Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA. 277:1058–63.CrossRefGoogle Scholar
  4. 4.
    Boomer JS, et al. (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 306:2594–605.CrossRefGoogle Scholar
  5. 5.
    Angus DC. (2010) The lingering consequences of sepsis: a hidden public health disaster? JAMA. 304:1833–4.CrossRefGoogle Scholar
  6. 6.
    Nathan C and Ding A. (2010) Nonresolving inflammation. Cell. 140:871–82.CrossRefGoogle Scholar
  7. 7.
    Xiao W, et al. (2011) A genomic storm in critically injured humans. J. Exp. Med. 208:2581–90.CrossRefGoogle Scholar
  8. 8.
    Angus DC, et al. (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit. Care Med. 35:1061–7.CrossRefGoogle Scholar
  9. 9.
    Stellwagen D and Malenka RC. (2006) Synaptic scaling mediated by glial TNF-alpha. Nature. 440:1054–9.CrossRefGoogle Scholar
  10. 10.
    Viviani B, et al. (2003) Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J. Neurosci. 23:8692–700.CrossRefGoogle Scholar
  11. 11.
    Yoshida T, et al. (2012) Interleukin-1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule. J. Neurosci. 32:2588–600.CrossRefGoogle Scholar
  12. 12.
    Terrando N, et al. (2010) Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc. Natl. Acad. Sci. U. S. A. 107:20518–22.CrossRefGoogle Scholar
  13. 13.
    Terrando N, et al. (2010) The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit Care. 14:R88.CrossRefGoogle Scholar
  14. 14.
    Goldstein RS, et al. (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock. 25:571–4.CrossRefGoogle Scholar
  15. 15.
    Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296–301.CrossRefGoogle Scholar
  16. 16.
    Li J, et al. (2004) Recombinant HMGB1 with cytokine-stimulating activity. J. Immunol. Methods. 289:211–23.CrossRefGoogle Scholar
  17. 17.
    Chang EH, Rigotti A and Huerta PT. (2009) Age-related influence of the HDL receptor SR-BI on synaptic plasticity and cognition. Neurobiol. Aging. 30:407–19.CrossRefGoogle Scholar
  18. 18.
    Irwin S. (1968) Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1:222–57.CrossRefGoogle Scholar
  19. 19.
    Rogers DC, et al. (1997) Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome. 8:711–3.CrossRefGoogle Scholar
  20. 20.
    Contet C, Rawlins JN and Deacon RM. (2001) Acomparison of 129S2/SvHsd and C57BL/ 6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice. Behav. Brain Res. 124:33–46.CrossRefGoogle Scholar
  21. 21.
    Deacon RM and Rawlins JN. (2002) Learning impairments of hippocampal-lesioned mice in a paddling pool. Behav. Neurosci. 116:472–8.CrossRefGoogle Scholar
  22. 22.
    DeGiorgio LA, et al. (2001) A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7:1189–93.CrossRefGoogle Scholar
  23. 23.
    Eilam-Stock T, Serrano P, Frankfurt M and Luine V. (2012) Bisphenol-A impairs memory and reduces dendritic spine density in adult male rats. Behav. Neurosci. 126:175–85.CrossRefGoogle Scholar
  24. 24.
    Wang H, et al. (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 164:1768–73.CrossRefGoogle Scholar
  25. 25.
    Ulloa L. (2011) The anti-inflammatory potential of selective cholinergic agonists. Shock. 36:97–8.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Sangeeta S Chavan
    • 1
  • Patricio T Huerta
    • 2
  • Sergio Robbiati
    • 2
  • S I Valdes-Ferrer
    • 1
  • Mahendar Ochani
    • 1
  • Meghan Dancho
    • 1
  • Maya Frankfurt
    • 3
  • Bruce T Volpe
    • 4
  • Kevin J Tracey
    • 1
  • Betty Diamond
    • 5
  1. 1.Laboratorie of Biomedical ScienceThe Feinstein Institute for Medical ResearchManhassetUSA
  2. 2.Laboratorie of Immune and Neural NetworksThe Feinstein Institute for Medical ResearchManhassetUSA
  3. 3.Department of Science EducationHofstra North Shore-LIJ School of MedicineHempsteadUSA
  4. 4.Laboratorie of Functional NeuroanatomyThe Feinstein Institute for Medical ResearchManhassetUSA
  5. 5.Center for Autoimmune and Musculoskeletal DiseasesThe Feinstein Institute for Medical ResearchManhassetUSA

Personalised recommendations